Maintaining optimal heart health after pregnancy can mitigate cardiovascular disease risk

Women with a history of adverse pregnancy complications are at significantly higher risk of developing heart disease but can reduce their risk by maintaining optimal heart health after pregnancy, according to preliminary research to be presented at the American Heart Association’s Epidemiology and Prevention│Lifestyle and Cardiometabolic Scientific Sessions 2024, March 18- 21, in Chicago.

CDC Alerts on Dramatic Rise in Human Parvovirus B19

The CDC alerted healthcare providers on Tuesday to a dramatic increase in human parvovirus B19 activity in the U.S. and Europe. The proportion of people

August 15, 2024

Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma

SAN DIEGO — Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta),

December 14, 2023

Risk Adjusted Net Present Value: What is the current valuation of Inhibikase Therapeutics’s Risvodetinib

The revenue for Risvodetinib is expected to reach an annual total of $42 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.